Oculis logo.png
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
February 07, 2025 18:35 ET | Oculis Holding AG
ZUG, Switzerland, Feb. 08, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares. ...
Matthews International Full Logo - Spot Red2.jpg
Matthews International Issues Statement Following ISS Report
February 07, 2025 18:30 ET | Matthews International Corporation
PITTSBURGH, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matthews International Corporation (Nasdaq GSM: MATW) (“Matthews” or the “Company”) issued the following statement regarding a February 6, 2025 report...
Pliant_logo_300x300.jpg
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
February 07, 2025 16:58 ET | Pliant Therapeutics, Inc.
Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed SOUTH SAN FRANCISCO,...
Neuronetics_logo-RGB purple.png
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025 16:30 ET | Neuronetics
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
blue_logo_stacked.jpg
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025 16:30 ET | Tempest Therapeutics
BRISBANE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
Fulcrum-Logo_Primary_Full-Color_RGB_Large.png
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025 16:30 ET | Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...
ORIC.png
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025 16:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that...
Logo.png
Callan JMB Announces Partial Exercise of Underwriters’ Over-Allotment Option in Connection with its Initial Public Offering
February 07, 2025 16:15 ET | Callan JMB Inc.
SPRING BRANCH, Texas, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB) (“Callan” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency...
brera-holdings logo.jpg
Brera Holdings Announces Anticipated Receipt of Nasdaq Additional Deficiency Notice
February 07, 2025 16:15 ET | Brera Holdings PLC
Dublin, Ireland, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Brera Holdings PLC (“Brera Holdings” or “the Company”) (Nasdaq: BREA), an Ireland-based, Nasdaq-listed, international holding company focused on...
mersana_logo.png
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025 16:05 ET | Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...